Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Association of Race/Ethnicity, Gender, and Socioeconomic Status With Sodium-Glucose Cotransporter 2 Inhibitor Use Among Patients With Diabetes in the US
Lauren A. Eberly, Lin Yang, Nwamaka D. Eneanya, et al.
JAMA Network Open (2021) Vol. 4, Iss. 4, pp. e216139-e216139
Open Access | Times Cited: 259

Showing 1-25 of 259 citing articles:

A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease
Cynthia Delgado, Mukta Baweja, Deidra C. Crews, et al.
American Journal of Kidney Diseases (2021) Vol. 79, Iss. 2, pp. 268-288.e1
Open Access | Times Cited: 564
Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)
Ian H. de Boer, Kamlesh Khunti, Tami Sadusky, et al.
Diabetes Care (2022) Vol. 45, Iss. 12, pp. 3075-3090
Open Access | Times Cited: 417
Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association
Chiadi E. Ndumele, Janani Rangaswami, Sheryl L. Chow, et al.
Circulation (2023) Vol. 148, Iss. 20, pp. 1606-1635
Open Access | Times Cited: 397
Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease
Kunihiro Matsushita, Shoshana H. Ballew, Angela Yee‐Moon Wang, et al.
Nature Reviews Nephrology (2022) Vol. 18, Iss. 11, pp. 696-707
Closed Access | Times Cited: 340
Sex differences in type 2 diabetes
Alexandra Kautzky‐Willer, Michael Leutner, Jürgen Harreiter
Diabetologia (2023) Vol. 66, Iss. 6, pp. 986-1002
Open Access | Times Cited: 247
A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease
Cynthia Delgado, Mukta Baweja, Deidra C. Crews, et al.
Journal of the American Society of Nephrology (2021) Vol. 32, Iss. 12, pp. 2994-3015
Open Access | Times Cited: 243
Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)
Ian H. de Boer, Kamlesh Khunti, Tami Sadusky, et al.
Kidney International (2022) Vol. 102, Iss. 5, pp. 974-989
Open Access | Times Cited: 170
Racial, Ethnic, and Socioeconomic Inequities in Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Diabetes in the US
Lauren A. Eberly, Lin Yang, Utibe R. Essien, et al.
JAMA Health Forum (2021) Vol. 2, Iss. 12, pp. e214182-e214182
Open Access | Times Cited: 142
National Trends in Use of Sodium‐Glucose Cotransporter‐2 Inhibitors and Glucagon‐like Peptide‐1 Receptor Agonists by Cardiologists and Other Specialties, 2015 to 2020
Rishav Adhikari, Kunal Jha, Zeina Dardari, et al.
Journal of the American Heart Association (2022) Vol. 11, Iss. 9
Open Access | Times Cited: 88
Association of Race and Ethnicity With Prescription of SGLT2 Inhibitors and GLP1 Receptor Agonists Among Patients With Type 2 Diabetes in the Veterans Health Administration System
Julio A. Lamprea‐Montealegre, Erin Madden, Sri Lekha Tummalapalli, et al.
JAMA (2022) Vol. 328, Iss. 9, pp. 861-861
Open Access | Times Cited: 78
Optimizing Foundational Therapies in Patients With HFrEF
Abhinav Sharma, Subodh Verma, Deepak L. Bhatt, et al.
JACC Basic to Translational Science (2022) Vol. 7, Iss. 5, pp. 504-517
Open Access | Times Cited: 71
Prevalence and Overlap of Cardiac, Renal, and Metabolic Conditions in US Adults, 1999-2020
John W. Ostrominski, Suzanne V. Arnold, Javed Butler, et al.
JAMA Cardiology (2023) Vol. 8, Iss. 11, pp. 1050-1050
Open Access | Times Cited: 63
Newer glucose‐lowering drugs and risk of dementia: A systematic review and meta‐analysis of observational studies
Huilin Tang, Hui Shao, C. Elizabeth Shaaban, et al.
Journal of the American Geriatrics Society (2023) Vol. 71, Iss. 7, pp. 2096-2106
Closed Access | Times Cited: 54
The role of structural racism and geographical inequity in diabetes outcomes
Shivani Agarwal, Alisha N. Wade, Jean Claude Mbanya, et al.
The Lancet (2023) Vol. 402, Iss. 10397, pp. 235-249
Open Access | Times Cited: 43
Screening, identifying, and treating chronic kidney disease: why, who, when, how, and what?
Douglas R. Farrell, Joseph A. Vassalotti
BMC Nephrology (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 17
Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus
Yuta Suzuki, Hidehiro Kaneko, Akira Okada, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 53
Prescription of guideline‐directed medical therapies in patients with diabetes and chronic kidney disease from the CURE‐CKD Registry, 2019‐2020
Susanne B. Nicholas, Kenn B. Daratha, Radica Z. Alicic, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 10, pp. 2970-2979
Open Access | Times Cited: 37
Socioeconomic aspects of incretin-based therapy
Thomas Karagiannis, Eleni Bekiari, Απόστολος Τσάπας
Diabetologia (2023) Vol. 66, Iss. 10, pp. 1859-1868
Open Access | Times Cited: 30
Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: A joint analysis of randomized controlled clinical trials
Hiddo J.L. Heerspink, Priya Vart, Niels Jongs, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 11, pp. 3327-3336
Closed Access | Times Cited: 30
Association of Prescription Co-payment With Adherence to Glucagon-Like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter-2 Inhibitor Therapies in Patients With Heart Failure and Diabetes
Utibe R. Essien, Balvindar Singh, Gretchen Swabe, et al.
JAMA Network Open (2023) Vol. 6, Iss. 6, pp. e2316290-e2316290
Open Access | Times Cited: 24
Prescribing patterns and factors associated with sodium–glucose cotransporter-2 inhibitor prescribing in patients with diabetes mellitus and atherosclerotic cardiovascular disease
Aya Ozaki, Dennis T. Ko, Alice Chong, et al.
CMAJ Open (2023) Vol. 11, Iss. 3, pp. E494-E503
Open Access | Times Cited: 24
Implementation of chronic kidney disease guidelines for sodium-glucose co-transporter-2 inhibitor use in primary care in the UK: a cross-sectional study
Anna Forbes, William Hinton, Michael Feher, et al.
EClinicalMedicine (2024) Vol. 68, pp. 102426-102426
Open Access | Times Cited: 14
Cystatin C should be routinely available for estimating kidney function
Jennifer S. Lees, June Fabian, Michael G. Shlipak
Current Opinion in Nephrology & Hypertension (2024) Vol. 33, Iss. 3, pp. 337-343
Closed Access | Times Cited: 9
Race and ethnicity and pharmacy dispensing of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes
Luis A. Rodríguez, Holly Finertie, Romain Neugebauer, et al.
The Lancet Regional Health - Americas (2024) Vol. 34, pp. 100759-100759
Open Access | Times Cited: 9
Sex difference in human diseases: mechanistic insights and clinical implications
Yuncong Shi, Jianshuai Ma, Sijin Li, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 9
Page 1 - Next Page

Scroll to top